MoonLake Immunotherapeutics (MLTX) nearly wiped its stock off the map Monday after the company posted mixed results for its highly anticipated skin disease treatment, sonelokimab. But only one of the final-phase studies met its goal, MoonLake Immunotherapeutics said over the weekend. In morning trades on today's stock market, MoonLake Immunotherapeutics shares crashed more than 89% to 6.60. He rates MoonLake Immunotherapeutics shares an outperform, but says his model is under review. He noted MoonLake may need to run an additional Phase 3 study to seek approval for its HS drug.